DR. MICHAEL TIMOTHY TEES M.D. M.P.H. NPI 1407023385

NPI Information

  • NPI: 1407023385
  • Provider Name: DR. MICHAEL TIMOTHY TEES, M.D., M.P.H.
  • Classification: Internal Medicine - 207RH0003X
  • Specialization: Hematology & Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 1721 E 19TH AVE STE 300
    DENVER, CO
    ZIP 80218
  • Phone: (720) 754-4800

Map and Directions

Get Directions

NPI Details

DR. Michael Timothy Tees, M.D., M.P.H. is a hematology and oncology internal medicine in Denver, CO with 18 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Michael Timothy Tees, M.D., M.P.H. NPI is 1407023385. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: TULANE UNIVERSITY SCHOOL OF MEDICINE
Graduation Year:2008

The provider's business location address is:

1721 E 19TH AVE STE 300
DENVER, CO
ZIP 80218-258
Phone: (720) 754-4800
Fax: (720) 754-4801

The NPI 1407023385 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA).

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
  • Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
  • Insertion of needle into vein for collection of blood sample (HCPCS:36415)
  • Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
  • Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Hospital discharge day management, more than 30 minutes (HCPCS:99239)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0220)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
  • Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)

The enumeration date for this NPI number is 5/10/2008 and was last updated on 12/8/2018.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207R00000XInternal Medicine55473COLORADONo
2207RH0003XInternal MedicineHematology & Oncology55473COLORADOYes
3207R00000XInternal Medicine255501NEW YORKNo
4207R00000XInternal MedicineME112656FLORIDANo

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.

No. Other Provider Identifier Other Provider Identifier Type Other Provider Identifier State Other Provider Identifier Issuer
196872039MEDICAIDCOLORADO

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.